Editor-in-Chief: Godefridus J. Peters
Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision: 63 days

Cancer Drug Resistance

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Articles

Most Recent | Most Viewed | Most Downloaded

The emerging role of GLP-1 receptor agonists in treating or preventing cancer

Open Access Commentary DOI: 10.20517/cdr.2024.116 6 Dec 2024
Views: Downloads:
Download PDF

Breast cancer cell resistance to hormonal and targeted therapeutics is correlated with the inactivation of the NR6A1 axis

Open Access Original Article DOI: 10.20517/cdr.2024.69 22 Nov 2024
Views: Downloads:
Download PDF

Mechanism of ferroptosis resistance in cancer cells

Open Access Review DOI: 10.20517/cdr.2024.127 19 Nov 2024
Views: Downloads:
Download PDF

HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond

Open Access Review DOI: 10.20517/cdr.2024.103 19 Nov 2024
Views: Downloads:
Download PDF

Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity

Open Access Review DOI: 10.20517/cdr.2024.131 18 Nov 2024
Views: Downloads:
Download PDF

Venetoclax resistance: mechanistic insights and future strategies

Open Access Review DOI: 10.20517/cdr.2021.125 5 May 2022
Views: Downloads:
Download PDF

Improving HER2 testing reproducibility in HER2-low breast cancer

Open Access Opinion DOI: 10.20517/cdr.2022.29 31 Aug 2022
Views: Downloads:
Download PDF

Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces

Open Access Review DOI: 10.20517/cdr.2022.20 1 Aug 2022
Views: Downloads:
Download PDF

Submission Deadline: 20 Apr 2025

Published articles: 0

Topic: Exosomes in Combating Cancer Drug Resistance

Submission Deadline: 15 Apr 2025

Published articles: 0

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Articles Collection
The journal Cancer Drug Resistance has established a media partnership with the 5th EMBL Partnership Conference AI in one health.
The journal Cancer Drug Resistance has established a media partnership with the European Molecular Biology Laboratory (EMBL) for the upcoming EMBL Symposium - Mechanisms of drug resistance and tolerance in bacteria, fungi, and cancer.
On November 4, 2024, the editorial team sat down with Prof. David A. Gewirtz, a leading scientist in oncology research and an esteemed member of the journal’s Editorial Board.
On September 16, 2024, Stanford University and Elsevier jointly released the list of the world’s top 2% scientists.
We are pleased to announce that our journal, Cancer Drug Resistance (CDR), has obtained a new Impact Factor 2023 of 4.6, as reported by the Journal Citation Reports (JCR) released by Clarivate Analytics on June 20, 2024.

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Submission Deadline: 20 Apr 2025

Published articles: 0

Topic: Exosomes in Combating Cancer Drug Resistance

Submission Deadline: 15 Apr 2025

Published articles: 0

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/